Ranbaxy Sues First Databank For Trade Libel Over Acne Drug

Law360, New York (July 18, 2013, 3:16 PM EDT) -- Ranbaxy Laboratories Inc. hit drug information publisher First Databank Inc. with a trade libel suit in Florida federal court Wednesday, saying FDB's database falsely indicates that Ranbaxy's Absorica acne drug can be safely substituted with certain other drugs, causing it more than $15 million in damages. 

The U.S. Food and Drug Administration has classified Absorica as a so-called single-source drug — those that can't be substituted by other drugs — but Ranbaxy says FDB's database is causing pharmacists to fill Absorica prescriptions with other drugs, putting...
To view the full article, register now.